The European Foregut Society (EFS) today represents the leading association in Europe for benign foregut disease and pre-malignancy.
Our Mission
The EFS fosters partnership and exchange of ideas throughout Europe, across disciplines and between clinicians in the management of patients with benign foregut disease and pre-malignancy. We encourage international multidisciplinary dialogue, education, and research. Our society is assisting in the development of benchmarks that improve diagnosis, treatment and outcomes for patients with foregut symptoms and we offer support for their implementation.
Fighting the foregut diseases
We want to be different! Traditional societies tend to focus mainly on cancer and bariatrics to the extent that benign disease is largely marginalized. The emphasis of EFS is on the collaboration of professionals to develop the best practice for patients with benign and premalignant foregut disease.
Multidisciplinary Pan – European Society
We offer the knowledge and expertise of leading experts across all parts of Europe, in the field of surgery, endoscopy, gastroenterology, pathology and radiology, to personalize treatment and improve patients outcomes.
EFS Story
EFS Annual Meeting
On behalf of the EFS Board It is with great pleasure that I invite you to the Annual Meeting from November, 5-7th 2024.
Dear Members and esteemed Colleagues,
On behalf of the EFS Board It is with great pleasure that I invite you to the Annual Meeting from November, 5-7th 2024. This year the meeting will be held in London and we’ll be delighted to welcome you to The Royal Society of Medicine. This fabulous venue is located in the centre of the historic medical district and in the very heart of the city.
This year’s meeting promises to build on what’s gone before. We will be exploring the latest trends, innovations and best practices in the field of the foregut. A rich and varied program awaits you including lectures by renowned experts, workshops and panel discussions. Perhaps above all, in the spirit of the EFS ethos this annual event presents a unique opportunity to bring everyone from all the specialities involved in the treatment of benign foregut conditions together to exchange the latest knowledge, forge new collaborations and above all have a great time.
London is a “world city” It is one of the most dynamic and culturally diverse capitals in Europe and will provide an unforgettable experience and inspiration for all participants. We can’t wait to welcome you!
See you in London in November!
EFS Postgraduate Course
2nd Belgrade postgraduate course
Current interventional management of gastroesophageal reflux disease
European Foregut Society (EFS) provides specialized platform for the thoughtful diagnostics and treatment of benign foregut diseases. Today, gastroesophageal reflux disease (GERD) represents an important clinical challenge starting from proper diagnosis to treatment strategies. As a chronic endemic progressive disease, GERD has a huge negative impact on health-related quality of life, and may lead to Barrett’s esophagus and adenocarcinoma. GERD is complex and heterogeneous disease requiring a patient-centered and multidisciplinary approach, with more than 1/3 of patients being partial responders or non-responders to proton-pump inhibitors, with a growing concern regarding the safety of long-term pharmacological therapy. Systematic assessment of symptoms, anatomy, physiology, histopathology and burden of reflux, are mandatory to plainly identify patients with progressive disease who may benefit from early interventional management.
Interventional GERD therapy can be performed either through minimally invasive surgery or flexible endoscopy. Both methods have the potential to reinforce the lower esophageal sphincter and the gastroesophageal flap valve in order to protect the esophageal mucosa from the reflux of both acid and alkaline gastric contents. However, as an important integral part of the antireflux barrier, a crural repair is feasible only through a laparoscopic approach.
